A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antibodies, Monoclonal; Methotrexate

Criteria

Inclusion Criteria:

• Have given written informed consent

• Women must not be at risk to become pregnant during study participation

• Diagnosis of Rheumatoid Arthritis (RA)

• Current, regular use of Methotrexate, at a stable dose

• Other criteria to be reviewed by study doctor

Exclusion Criteria:

• Use of excluded medications(reviewed by study doctor)

• Have not failed biologic tumor necrosis factor-alpha (TNF-α) inhibitor therapy

• Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation in the study

• Evidence of tuberculosis

• Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy

• Other criteria to be reviewed by study doctor